Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)
Clinical trial of BAY43-9006 in patients with hepatocellular carcinoma.
Carcinoma, Hepatocellular
DRUG: Sorafenib (Nexavar, BAY43-9006)|DRUG: Placebo
Time to Progression (TTP), Time to progression (TTP) was defined as the time from date of randomization to radiological progression / recurrence. Subjects without progression at the time of analysis were censored at their last date of tumor evaluation., From randomization of the first subject until radiological progression or recurrence whichever came first, assessed up to 39 months.
Overall Survival (OS), Overall survival (OS) was defined as the time from date of randomization to death due to any cause. Subjects still alive at their last date of follow-up were censored at the time of analysis., From randomization of the first subject until 39 months later.
Clinical trial of BAY43-9006 in patients with hepatocellular carcinoma.